Charles River Laboratories

Matthew Hewitt, Ph.D., Vice President, Chief Technology Officer, Manufacturing Business Division

Wilmington, MA

(NASDAQ: CRL)

The advanced therapeutic space continues to evolve at a rapid pace. Since the beginning of 2023, the FDA has approved 12 commercial CGTs and the pace is quickening. In addition, regulators have released multiple pieces of guidance to inform CGT stakeholders about FDA and EMA’s expectations. It’s become more important than ever for therapeutic developers to work with partners who understand and can navigate this evolving landscape. Separate from regulatory guidance, other topics are being discussed such as efficiently scaling manufacturing to meet market demand and decentralized manufacturing. Charles River Laboratories (CRL) has combined its substantial knowledge with industry-leading services and platforms to assemble a concept-to-cure advanced therapeutics portfolio. In this talk, CRL will examine trends in the field, discuss our approach to address challenges, and explain how we assist partners and enable them to bring potentially curative, life-saving therapies to patients.

www.criver.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions